Christopher Czura

Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…


Battelle superstar to head bioelectronics center

Chad Bouton, an expert in decoding the brain waves that have allowed paralyzed patients to move or operate a wheel chair by thought alone, has been named managing director of the Feinstein Institute’s new Center for Bioelectronic Medicine. The $300 million center, planned for the Nassau Hub area in Uniondale, will bring together scientists and medical experts to research and commercialize non-drug treatments for such conditions as rheumatoid arthritis, diabetes, gastric conditions and others, including…


Feinstein, Battelle partner on ‘Neural Tourniquet’

North Shore-LIJ’s Feinstein Institute is partnering with Ohio health giant Battelle on a so-called Neural Tourniquet that will reshape the way doctors staunch blood loss, from the battlefield to the operating room. The technology is an outgrowth of research pioneered by Feinstein director Kevin Tracey, whose discoveries have helped fuel the bioelectronic medicine field, which combines molecular medicine, bioengineering and neuroscience to develop nerve-stimulating and sensing technologies to regulate biological processes. Tracey’s discoveries have already…